FINCK BARBARA K 4/A
4/A · Comera Life Sciences Holdings, Inc. · Filed Feb 14, 2023
Insider Transaction Report
Form 4/AAmended
FINCK BARBARA K
Director
Transactions
- Purchase
Warrant (Right to Buy)
2023-01-04$0.25/sh+6,756$1,689→ 6,756 totalExercise: $1.23From: 2023-01-04Exp: 2028-01-04→ Common Stock (13,512 underlying) - Purchase
Common Stock
2023-01-04$1.23/sh+6,756$8,310→ 23,033 total
Footnotes (3)
- [F1]This Form 4/A is being filed to (i) correct a typographical error in the transaction code disclosed in Column 3 in Table I and Column 4 in Table II in the original Form 4, filed on January 6, 2023, from "A" to "P" and (ii) correct a typographical error in the power-of-attorney of the reporting person.
- [F2]The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 6,756 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules.
- [F3]The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation.